Industries > Pharma > Top Companion Diagnostic Companies: Competitive Analysis 2013-2023

Top Companion Diagnostic Companies: Competitive Analysis 2013-2023

PUBLISHED: 09 January 2013
PAGES: 157
PRODUCT CODE:
SUBMARKET: Diagnostics

Clear
WOOCS 2.2.1
SKU: N/A Categories: ,

A myriad of pharmaceutical and diagnostic companies are now entering the highly attractive market of companion diagnostics, many of them entering into collaborations for developing a combination product. Apart from the well-known pharmaceutical and diagnostic companies, some small, niche-companies are also focusing on companion diagnostic development. At present, competition is largely dependent on the ability to collaborate with biotechnology and pharmaceutical companies to develop and commercialise these tests for their therapeutic drugs and drug candidates. The number of partnerships between the two industries will keep expanding as most pharmaceutical companies do not have an in-house diagnostic capability for either the development of a companion diagnostic or the commercialisation of the test once the drug is approved.

Top Companion Diagnostic Companies: Competitive Analysis 2013-2023 analyses the top 12 companies involved in the companion diagnostics market. This report also provides our sales forecasts, market share analyses, discussions of technological developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 125 tables and figures included. The result is a comprehensive market, and industry-centred study, with detailed analyses and informed opinion to benefit your work. Visiongain has determined that the value of the global companion diagnostics market will reach $19.3bn in 2023.

What makes this report unique?

Visiongain consulted widely with industry experts and full transcripts from these exclusive interviews are included in the report. As such, our reports have a unique blend of primary and secondary sources providing informed opinion. The report provides insight into key drivers and restraints facing the industry, as well as identifying leading companies. The report also provides a unique blend of qualitative analysis combined with extensive quantitative data including global, submarket and national markets forecasts from 2012-2023 – all highlighting key business opportunities.

Why you should buy Top Companion Diagnostic Companies: Competitive Analysis 2013-2023

• 137 pages of comprehensive analysis
• 1 Exclusive Visiongain interviews with experts from-
– Myriad Genetics
• 125 tables, charts, and graphs
• Companion diagnostic market forecast between 2012-2023
• 2 companion diagnostic submarket forecasts from 2012-2023
– Theranostics
– Other companion diagnostics
• A SWOT analysis
• Several leading companies identified and 12 profiled –
Roche, Dako, QIAGEN, Abbott, Life Technologies, LabCorp, Genomic Health, MDxHealth, bioMerieux, Johnson and Johnson, Siemens and Myriad Genetics

You can order this report today

Gain an understanding of the overall companion diagnostics market and the leading companies operating in this market by ordering Top Companion Diagnostic Companies: Competitive Analysis 2013-2023.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Top Companion Diagnostic Companies: Competitive Analysis 2013-2023


Download sample pages

Complete the form below to download your free sample pages for Top Companion Diagnostic Companies: Competitive Analysis 2013-2023


Latest Pharma news

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Categories